Lack of interleukin‐6 in the tumor microenvironment augments type‐1 immunity and increases the efficacy of cancer immunotherapy
Yosuke Ohno(Hokkaido University), Hidemitsu Kitamura(Toyo University), Shinichi Hashimoto(Wakayama Medical University), Shigenori Homma(Hokkaido University), Kazuho Ikeo(National Institute of Genetics), Huihui Xiang, Shun Kaneumi(Hokkaido University), Satoshi Terada(Hokkaido University), Norikazu Monma(National Institute of Genetics), Akinobu Taketomi(Hokkaido University), Yujiro Toyoshima(Hokkaido University), Hideki Kawamura(Hokkaido University), Norihiko Takahashi(The University of Tokyo), Kentaro Sumida(Hokkaido University), Hideaki Yurino(Kanazawa University)
Cited by 85
Related Papers
Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA
|Nature Genetics|1993|490
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Curated genome annotation of<i>Oryza sativa</i>ssp.<i>japonica</i>and comparative genome analysis with<i>Arabidopsis thaliana</i>
|Genome Research|2007|275
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267